Top

Published in:

01-12-2010

Depression, Selective Serotonin Reuptake Inhibitors, and Osteoporosis

Authors: Itai Bab, Raz Yirmiya

Published in: Current Osteoporosis Reports | Issue 4/2010

Abstract

An increasing number of studies suggest an association between depression and osteoporosis. In a mouse model, depression induces bone loss, mediated by brain-to-bone sympathetic signaling. Depression and bone antianabolic sympathetic tone are alleviated by increasing central serotonin (5-hydroxytryptamine, 5-HT) levels. However, selective serotonin reuptake inhibitors (SSRIs), the first-line antidepressants, increase extracellular 5-HT levels but have deleterious skeletal effects. The skeletal serotonergic system consists of 5-HT receptors and the 5-HT transporter (5-HTT) in osteoblasts and osteocytes. 5-HTT is a transmembrane protein targeted by SSRIs. 5-HT restrains osteoblastic activity, thus leading to bone loss. Apparently, the negative skeletal effects of the peripheral SSRI-induced increase in 5-HT outweighs the skeletal benefits resulting from the enhanced central 5-HT antidepressant and antisympathetic activity. Overall, major depression appears as an important risk factor for osteoporosis. However, antidepressants, mainly SSRIs, should be evaluated in view of the causal relationship between depression and bone loss, and vis-à-vis their skeletal adverse effects. Patients with depressive disorders should undergo a routine skeletal evaluation and receive timely antiosteoporotic therapy, especially when SSRI treatment is prescribed.

•• Yirmiya R, Bab I: Major depression is a risk factor for low bone mineral density: a meta-analysis. Biol Psychiatry 2009, 66:423–432. This article reports the most comprehensive meta-analysis demonstrating a significant correlation between MDD and low bone mass, which is stronger in women than in men and in pre- than postmenopausal women. The article further provides a review of the studies dealing with depression and bone and portrays depression as a risk factor for osteoporosis.CrossRefPubMed

Murray CJ, Lopez AD: Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498–1504.CrossRefPubMed

Riggs BL, Khosla S, Melton LJ 3rd: Sex steroids and the construction and conservation of the adult skeleton. Endocr Rev 2002, 23:279–302.CrossRefPubMed

Diagnostic and Statistical Manual of Mental Disorders. Fourth Edition. Arlington, VA: American Psychiatric Association; 1994.

• Cizza G, Primma S, Coyle M, et al.: Depression and osteoporosis: a research synthesis with meta-analysis. Horm Metab Res 2010, 42:467–482. This study shows that the low BMD is associated with MDD and involves the anterior-posterior spine, femoral neck, and total femur, suggesting that depression-associated low bone mass is site independent.CrossRefPubMed

• Wu Q, Magnus JH, Liu J, et al.: Depression and low bone mineral density: a meta analysis of epidemiologic studies. Osteoporos Int 2009, 20:1309–1320. This meta-analysis found that depression is associated with a significantly decreased BMD, with a substantially lower BMD in depressed women and in cases of clinical depression.CrossRefPubMed

•• Yirmiya R, Goshen I, Bajayo A, et al.: Depression induces bone loss through stimulation of the sympathetic nervous system. Proc Natl Acad Sci U S A 2006, 103:16876–16881. Using CMS, a mouse model for depression, this article suggests a causal relationship whereby depression induces bone loss, mainly by inhibiting bone formation. The article further portrays the sympathetic nervous system as the main pathway communicating depressive signals to the skeleton.CrossRefPubMed

• Dorn LD, Susman EJ, Pabst S, et al.: Association of depressive symptoms and anxiety with bone mass and density in ever-smoking and never-smoking adolescent girls. Arch Pediatr Adolesc Med 2008, 162:1181–1188. Consistent with the increased association between depression and low bone mass in premenopausal women, this article demonstrates an association between depressive symptoms and low bone density in adolescent girls, implicating depression in the inhibition of bone mass accrual.CrossRefPubMed

Gold DT, Solimeo S: Osteoporosis and depression: a historical perspective. Curr Osteoporos Rep 2006, 4:134–139.CrossRefPubMed

10.

Ilias I, Alesci S, Gold PW, Chrousos GP: Depression and osteoporosis in men: association or casual link? Hormones (Athens) 2006, 5:9–16.

11.

Weinstein RS, Jilka RL, Parfitt AM, Manolagas SC: Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998, 102:274–282.CrossRefPubMed

12.

Elefteriou F: Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 2008, 473:231–236.CrossRefPubMed

13.

Lu XY: The leptin hypothesis of depression: a potential link between mood disorders and obesity? Curr Opin Pharmacol 2007, 7:648–652.CrossRefPubMed

14.

Karsenty G: Convergence between bone and energy homeostases: leptin regulation of bone mass. Cell Metab 2006, 4:341–348.CrossRefPubMed

15.

Tam J, Trembovler V, Di Marzo V, Petrosino S, et al.: The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J 2008, 22:285–294.CrossRefPubMed

16.

Hill MN, Carrier EJ, McLaughlin RJ, et al.: Regional alterations in the endocannabinoid system in an animal model of depression: effects of concurrent antidepressant treatment. J Neurochem 2008, 106:2322–2336.CrossRefPubMed

17.

Bajayo A, Goshen I, Feldman S, et al.: Central IL-1 receptor signaling regulates bone growth and mass. Proc Natl Acad Sci U S A 2005, 102:12956–12961.CrossRefPubMed

18.

Goshen I, Kreisel T, Ben-Menachem-Zidon O, et al.: Brain interleukin-1 mediates chronic stress-induced depression in mice via adrenocortical activation and hippocampal neurogenesis suppression. Mol Psychiatry 2008, 13:717–728.CrossRefPubMed

19.

Adler UC, Marques AH, Calil HM: Inflammatory aspects of depression. Inflamm Allergy Drug Targets 2008, 7:19–23.CrossRefPubMed

20.

Mundy GR: Osteoporosis and inflammation. Nutr Rev 2007, 65:S147–S151.CrossRefPubMed

21.

Yu B, Becnel J, Zerfaoui M, et al.: Serotonin 5-hydroxytryptamine(2A) receptor activation suppresses tumor necrosis factor-alpha-induced inflammation with extraordinary potency. J Pharmacol Exp Ther 2008, 327:316–323.CrossRefPubMed

22.

Roggia C, Gao Y, Cenci S, et al.: Up-regulation of TNF-producing T cells in the bone marrow: a key mechanism by which estrogen deficiency induces bone loss in vivo. Proc Natl Acad Sci U S A 2001, 98:13960–13965.CrossRefPubMed

23.

Poirier MF, Canceil O, Baylé F, et al.: Prevalence of smoking in psychiatric patients. Prog Neuropsychopharmacol Biol Psychiatry 2002, 26:529–537.CrossRefPubMed

24.

Klungsøyr O, Nygård JF, Sørensen T, Sandanger I: Cigarette smoking and incidence of first depressive episode: an 11-year, population-based follow-up study. Am J Epidemiol 2006, 163:421–432.CrossRefPubMed

25.

Steuber TL, Danner F: Adolescent smoking and depression: which comes first? Addict Behav 2006, 31:133–136.CrossRefPubMed

26.

Lorentzon M, Mellström D, Haug E, Ohlsson C: Smoking is associated with lower bone mineral density and reduced cortical thickness in young men. J Clin Endocrinol Metab 2007, 92:497–503.CrossRefPubMed

27.

Gerdhem P, Obrant KJ: Effects of cigarette-smoking on bone mass as assessed by dual-energy X-ray absorptiometry and ultrasound. Osteoporos Int 2002, 13:932–936.CrossRefPubMed

28.

Chakkalakal DA: Alcohol-induced bone loss and deficient bone repair. Alcohol Clin Exp Res 2005, 29:2077–2090.CrossRefPubMed

29.

Turner RT, Sibonga JD: Effects of alcohol use and estrogen on bone. Alcohol Res Health 2001, 25:276–281.PubMed

30.

Zalloua PA, Hsu YH, Terwedow H, et al.: Impact of seafood and fruit consumption on bone mineral density. Maturitas 2007, 56:1–11.CrossRefPubMed

31.

Kroeze WK, Kristiansen K, Roth BL: Molecular biology of serotonin receptors structure and function at the molecular level. Curr Top Med Chem 2002, 2:507–528.CrossRefPubMed

32.

Raymond JR, Mukhin YV, Gelasco A, et al.: Multiplicity of mechanisms of serotonin receptor signal transduction. Pharmacol Ther 2001, 92:179–212.CrossRefPubMed

33.

Talley NJ: Serotoninergic neuroenteric modulators. Lancet 2001, 358:2061–2068.CrossRefPubMed

34.

Wade PR, Chen J, Jaffe B, et al.: Localization and function of a 5-HT transporter in crypt epithelia of the gastrointestinal tract. J Neurosci 1996, 16:2352–2364.PubMed

35.

McNicol A, Israels SJ: Platelet dense granules: structure, function and implications for haemostasis. Thromb Res 1999, 95:1–18.CrossRefPubMed

36.

Egermayer P, Town GI, Peacock AJ: Role of serotonin in the pathogenesis of acute and chronic pulmonary hypertension. Thorax 1999, 54:161–168.CrossRefPubMed

37.

Lee SL, Wang WW, Lanzillo JJ, Fanburg BL: Serotonin produces both hyperplasia and hypertrophy of bovine pulmonary artery smooth muscle cells in culture. Am J Physiol 1994, 266:L46–L52.PubMed

38.

Warden SJ, Bliziotes MM, Wiren KM, et al.: Neural regulation of bone and the skeletal effects of serotonin (5-hydroxytryptamine). Mol Cell Endocrinol 2005, 242:1–9.CrossRefPubMed

39.

Cherian PP, Cheng B, Gu S, et al.: Effects of mechanical strain on the function of Gap junctions in osteocytes are mediated through the prostaglandin EP2 receptor. J Biol Chem 2003, 278:43146–43156.CrossRefPubMed

40.

Bliziotes M, Eshleman A, Burt-Pichat B, et al.: Serotonin transporter and receptor expression in osteocytic MLO-Y4 cells. Bone 2006, 39:1313–1321.CrossRefPubMed

41.

Rand M, Reid G: Source of ‘serotonin’ in serum. Nature 1951, 168:385.CrossRefPubMed

42.

•• Yadav VK, Ryu J-H, Suda N, et al.: Lrp5 controls bone formation by inhibiting serotonin synthesis in the duodenum. Cell 2008, 135:825–837. This article shows that gut-derived 5-HT reaches bone via the blood circulation and inhibits osteoblast proliferation, bone formation, and bone density by activating osteoblastic Htr1b receptor and CREB. It is the first report implicating gut- rather than bone cell-derived 5-HT in the regulation of skeletal remodeling.CrossRefPubMed

43.

Yadav VK, Balaji S, Suresh PS, et al.: Pharmacological inhibition of gut-derived serotonin synthesis is a potential bone anabolic treatment for osteoporosis. Nat Med 2010, 16:308–312.CrossRefPubMed

44.

• Collet C, Schiltz C, Geoffroy V, et al.: The serotonin 5-HT2B receptor controls bone mass via osteoblast recruitment and proliferation. FASEB J 2008, 22:418–427. This article reports a low bone mass phenotype in female Htr2b receptor null mice, due to restrained osteoblast recruitment. Compared with Yadav et al. [42••], these findings suggest an opposite skeletal role for 5-HT, namely, stimulation of bone formation and bone mass.CrossRefPubMed

45.

Gustafsson BI, Westbroek I, Waarsing JH, et al.: Long-term serotonin administration leads to higher bone mineral density, affects bone architecture, and leads to higher femoral bone stiffness in rats. J Cell Biochem 2006, 97:1283–1291.CrossRefPubMed

46.

Bonnet N, Bernard P, Beaupied H, et al.: Various effects of antidepressant drugs on bone microarchitectecture, mechanical properties and bone remodeling. Toxicol Appl Pharmacol 2007, 221:111–118.CrossRefPubMed

47.

•• Yadav VK, Oury F, Suda N, et al.: A serotonin-dependent mechanism explains the leptin regulation of bone mass, appetite, and energy expenditure. Cell 2009, 138:976–989. This article shows that 5-HT in the brain downregulates the skeletal antianabolic sympathetic tone, thus assigning opposite skeletal effects to central and peripheral 5-HT signaling.CrossRefPubMed

48.

Ziere G, Dieleman JP, van der Cammen TJ, et al.: Selective serotonin reuptake inhibiting antidepressants are associated with an increased risk of nonvertebral fractures. J Clin Psychopharmacol 2008, 28:411–417.CrossRefPubMed

Title: Depression, Selective Serotonin Reuptake Inhibitors, and Osteoporosis
Authors: Itai Bab
Raz Yirmiya
Publication date: 01-12-2010
Publisher: Current Science Inc.
Published in: Current Osteoporosis Reports / Issue 4/2010
Print ISSN: 1544-1873
Electronic ISSN: 1544-2241
DOI: https://doi.org/10.1007/s11914-010-0026-z

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Depression, Selective Serotonin Reuptake Inhibitors, and Osteoporosis

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2010

Biomechanics of Vertebral Fractures and the Vertebral Fracture Cascade

The Definition and Clinical Significance of Nonvertebral Fractures

The Utility and Limitations of FRAX: A US Perspective

Bone Loss in Diabetes: Use of Antidiabetic Thiazolidinediones and Secondary Osteoporosis

The Skeletal Subsystem as an Integrative Physiology Paradigm

Denosumab for the Treatment of Osteoporosis